Pembrolizumab + Standard of care therapy
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Penile Carcinoma
Conditions
Penile Carcinoma
Trial Timeline
Jun 15, 2020 → Nov 13, 2023
NCT ID
NCT04224740About Pembrolizumab + Standard of care therapy
Pembrolizumab + Standard of care therapy is a phase 2 stage product being developed by Merck for Penile Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04224740. Target conditions include Penile Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04224740 | Phase 2 | Completed |
Competing Products
8 competing products in Penile Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Avelumab + enfortumab vedotin | Astellas Pharma | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Arm A: Atezolizumab and Radiotherapy + Arm B: Atezolizumab | Roche | Phase 2 | 52 |
| Placebo QHS and sildenafil and questionnaires + Sildenafil and questionnaire + Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires | Pfizer | Pre-clinical | 22 |
| Dacomitinib | Pfizer | Phase 2 | 51 |
| Avelumab | Pfizer | Phase 2 | 51 |
| Cabazitaxel | Sanofi | Phase 2 | 51 |
| Retifanlimab | Incyte | Phase 2 | 49 |